|
EVENT  SMi's 9th Annual Orphan Drugs & Rare Diseases Conference Evaluating the Key Challenges to Advance Commercialisation & Patient Access Conference: 15 - 16 October 2019 Workshop: 17 October 2019 Holiday Inn Kensington Forum, Copthorne Tara Hotel, London, UK Early bird offer SAVE £400 - Register here (Early bird expires this month) SMi Group are delighted to inform you of SMi’s 9th Annual Orphan Drugs & Rare Diseases Conference taking place at the Holiday Inn Kensington Forum, in London, UK on 15th and 16th October 2019. The 2-day full agenda/programme and the expert speaker line-up will be available to download here Early bird offer: you can save £400 off the full ticket price only available until May 2019. About the conference The 2-day conference will be chaired by Rick Thompson, CEO at Findacure Dr Rick Thompson joined Findacure in 2015, after completing his PhD in Evolutionary Biology at the University of Cambridge. He began working as Findacure’s first Scientific Officer, helping to develop the charity’s proof of concept study for the innovative drug repurposing social impact bond. Having been promoted to CEO in May 2017, Rick now oversees the charity’s strategy and development, oversees major funding applications, and manages the team, while still maintaining Findacure’s scientific projects. Rick is always keen to speak about Findacure’s work and aims to encourage industry engagement with rare disease patient groups, promoting an open and collaborative approach to rare disease research and patient support. You will hear from the experts, including: • Katrin Radl, Senior Manager Evidence Generation & Patient Access, Takeda • Sheela Upadhyaya,HST Associate Director, NICE • Mike Page, Executive Director Global Regulatory Affairs Portfolio Products, Alexion Pharmaceuticals • Donatello Crocetta,VP Global Head Rare Immunology Franchise, Takeda • Martin Garau, Associate Director, Office of Health Economics • Jayne Spink, CEO, Genetic Alliance UK To view the full speaker line-up please visit the website Evaluating the key challenges to advance commercialisation and patient access, the sessions include: • Assessment of the collaboration of pharmaceutical companies and investors • SPOTLIGHT PRESENTATION: Improving patient access to orphan medicinal products • Overview of current orphan drug regulation • OPENING ADDRESS: Collaborations in rare disease research and commercialisation • Charting the path to diagnosis for patients with rare diseases • CHIESI CASE STUDY: Holuclar • Early access for orphan drugs Who Should Attend: CEOs, CSOs, Vice Presidents, Directors, Heads, Principals working in: • Medical Affairs • Medical Advisory • Clinical Operations • Rare Disease Research • Patient Advocacy • Commercial Officer • Orphan Drug Therapeutics • Healthcare • Regulatory Affairs • Rare Disease Charity Officers • And for those who work or have an interest in orphan drugs and rare diseases PLUS! Interactive Workshop Thursday 17th October 2019 - 08.30 - 12.30 A deep dive into strategies for accelerating patient access of orphan drugs Workshop Leader: Solange Corriol-Rohou, Senior Director Regulatory Affairs & Policy Europe, AstraZeneca Are you interested in speaking, sponsoring or exhibiting at the event? Contact Alia Malick, Director, on +44 (0) 207 827 6168 or email amalick@smi-online.co.uk Take full advantage of the early bird offer and SAVE £400 Register online by clicking here The SMi Group team look forward to meeting you in London in October 2019! #SMiOrphanDrugs www.orphandrugs.co.uk/EM1rarerev P.S: Would you like to bring along a colleague? Take advantage of the group discount offer - speak to Kieran on +44 (0) 207 827 6174 today!
0 Comments
Leave a Reply. |